{"id":21018,"date":"2014-05-02T11:47:14","date_gmt":"2014-05-02T15:47:14","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=21018"},"modified":"2014-05-02T11:47:14","modified_gmt":"2014-05-02T15:47:14","slug":"endocyte-inc-nasdaqecyt-fell-the-deepest-in-3-years-after-failed-results-of-ovarian-cancer-drug-trail","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-fell-the-deepest-in-3-years-after-failed-results-of-ovarian-cancer-drug-trail-21018","title":{"rendered":"Endocyte, Inc. (NASDAQ:ECYT) Fell The Deepest In 3 Years After Failed Results Of Ovarian Cancer Drug Trail"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 05\/02\/2014 (wallstreetpr) &#8211;\u00a0<b>Endocyte, Inc. (NASDAQ:ECYT)<\/b> fell the most in three years following halt in its ovarian cancer treating drug analysis.<\/p>\n<p style=\"text-align: justify;\">The company\u2019s shares fell 63% after its cancer drug\u2019s trail was stopped because of failure to help patients. The drug trail was being conducted with the help of Merck &amp; Co., Inc. (NYSE:MRK). In a late stage trail, the drug, vintafolide, failed to demonstrate efficacy in treating patients having platinum resistant cancer. The study was stopped in Phase III, the company announced in a statement today.<\/p>\n<p style=\"text-align: justify;\">The West Lafayette, Indiana based company fell as much as 62%, down to $6.65 in the early hours of trading. This is Endocyte\u2019s deepest intraday fall since Dec 2011. Merck, which enjoyed rights to sell the drug, also fell 1.3% and reached $58.87.<\/p>\n<p style=\"text-align: justify;\"><b>Next Study<\/b><\/p>\n<p style=\"text-align: justify;\">Endocyte, Inc. (NASDAQ:ECYT), however, seeks to continue with the trail of vintafolide for lung cancer treatment, a late phase study results for which is due by the end of 2014. In this context, an analyst for RBC Capital Markets, Adnan butt, said that the company\u2019s lung cancer trail of the drug is more important as the market for the treatment is bigger as compared to that for ovarian cancer. He further said that it was quite unexpected for the trail to stop at Phase II trial. This is because of the promising results the drug had earlier demonstrated for study of non small cell lung cancer as well as other studies. Butt believes that until Endocyte, Inc. (NASDAQ:ECYT) comes up with the data for the lung cancer study, its share prices will be overpenalized.<\/p>\n<p style=\"text-align: justify;\"><b>Merck May Withdraw<\/b><\/p>\n<p style=\"text-align: justify;\">In a conference call with investors, Endocyte, Inc. (NASDAQ:ECYT)\u2019s management announced that the participating Whitehouse Station, New Jersey based company Merck may opt to withdraw support in the next study. A final and confirming decision, nevertheless, is due to be informed after the company has reviewed full data.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 05\/02\/2014 (wallstreetpr) &#8211;\u00a0Endocyte, Inc. (NASDAQ:ECYT) fell the most in three years following halt in its ovarian cancer treating drug analysis. The company\u2019s shares [&hellip;]<\/p>\n","protected":false},"author":32,"featured_media":21034,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[5412,5413],"stock_ticker":[],"class_list":["post-21018","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-endocyte-inc-nasdaqecyt","tag-nasdaqecyt","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Endocyte, Inc. (NASDAQ:ECYT) Fell The Deepest In 3 Years After Failed Results Of Ovarian Cancer Drug Trail - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-fell-the-deepest-in-3-years-after-failed-results-of-ovarian-cancer-drug-trail-21018\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Endocyte, Inc. (NASDAQ:ECYT) Fell The Deepest In 3 Years After Failed Results Of Ovarian Cancer Drug Trail - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 05\/02\/2014 (wallstreetpr) &#8211;\u00a0Endocyte, Inc. (NASDAQ:ECYT) fell the most in three years following halt in its ovarian cancer treating drug analysis. The company\u2019s shares [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-fell-the-deepest-in-3-years-after-failed-results-of-ovarian-cancer-drug-trail-21018\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-05-02T15:47:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/Endocyte-Inc..gif\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"512\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/gif\" \/>\n<meta name=\"author\" content=\"Greg Folin\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Greg Folin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-fell-the-deepest-in-3-years-after-failed-results-of-ovarian-cancer-drug-trail-21018#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-fell-the-deepest-in-3-years-after-failed-results-of-ovarian-cancer-drug-trail-21018\"},\"author\":{\"name\":\"Greg Folin\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\"},\"headline\":\"Endocyte, Inc. (NASDAQ:ECYT) Fell The Deepest In 3 Years After Failed Results Of Ovarian Cancer Drug Trail\",\"datePublished\":\"2014-05-02T15:47:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-fell-the-deepest-in-3-years-after-failed-results-of-ovarian-cancer-drug-trail-21018\"},\"wordCount\":338,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-fell-the-deepest-in-3-years-after-failed-results-of-ovarian-cancer-drug-trail-21018#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/Endocyte-Inc..gif\",\"keywords\":[\"Endocyte Inc. (NASDAQ:ECYT)\",\"NASDAQ:ECYT\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-fell-the-deepest-in-3-years-after-failed-results-of-ovarian-cancer-drug-trail-21018#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-fell-the-deepest-in-3-years-after-failed-results-of-ovarian-cancer-drug-trail-21018\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-fell-the-deepest-in-3-years-after-failed-results-of-ovarian-cancer-drug-trail-21018\",\"name\":\"Endocyte, Inc. (NASDAQ:ECYT) Fell The Deepest In 3 Years After Failed Results Of Ovarian Cancer Drug Trail - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-fell-the-deepest-in-3-years-after-failed-results-of-ovarian-cancer-drug-trail-21018#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-fell-the-deepest-in-3-years-after-failed-results-of-ovarian-cancer-drug-trail-21018#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/Endocyte-Inc..gif\",\"datePublished\":\"2014-05-02T15:47:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-fell-the-deepest-in-3-years-after-failed-results-of-ovarian-cancer-drug-trail-21018#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-fell-the-deepest-in-3-years-after-failed-results-of-ovarian-cancer-drug-trail-21018\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-fell-the-deepest-in-3-years-after-failed-results-of-ovarian-cancer-drug-trail-21018#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/Endocyte-Inc..gif\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/Endocyte-Inc..gif\",\"width\":1024,\"height\":512},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-fell-the-deepest-in-3-years-after-failed-results-of-ovarian-cancer-drug-trail-21018#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Endocyte, Inc. (NASDAQ:ECYT) Fell The Deepest In 3 Years After Failed Results Of Ovarian Cancer Drug Trail\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\",\"name\":\"Greg Folin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"caption\":\"Greg Folin\"},\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Endocyte, Inc. (NASDAQ:ECYT) Fell The Deepest In 3 Years After Failed Results Of Ovarian Cancer Drug Trail - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-fell-the-deepest-in-3-years-after-failed-results-of-ovarian-cancer-drug-trail-21018","og_locale":"en_US","og_type":"article","og_title":"Endocyte, Inc. (NASDAQ:ECYT) Fell The Deepest In 3 Years After Failed Results Of Ovarian Cancer Drug Trail - Wall Street PR","og_description":"Boston, MA 05\/02\/2014 (wallstreetpr) &#8211;\u00a0Endocyte, Inc. (NASDAQ:ECYT) fell the most in three years following halt in its ovarian cancer treating drug analysis. The company\u2019s shares [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-fell-the-deepest-in-3-years-after-failed-results-of-ovarian-cancer-drug-trail-21018","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-05-02T15:47:14+00:00","og_image":[{"width":1024,"height":512,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/Endocyte-Inc..gif","type":"image\/gif"}],"author":"Greg Folin","twitter_misc":{"Written by":"Greg Folin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-fell-the-deepest-in-3-years-after-failed-results-of-ovarian-cancer-drug-trail-21018#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-fell-the-deepest-in-3-years-after-failed-results-of-ovarian-cancer-drug-trail-21018"},"author":{"name":"Greg Folin","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e"},"headline":"Endocyte, Inc. (NASDAQ:ECYT) Fell The Deepest In 3 Years After Failed Results Of Ovarian Cancer Drug Trail","datePublished":"2014-05-02T15:47:14+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-fell-the-deepest-in-3-years-after-failed-results-of-ovarian-cancer-drug-trail-21018"},"wordCount":338,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-fell-the-deepest-in-3-years-after-failed-results-of-ovarian-cancer-drug-trail-21018#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/Endocyte-Inc..gif","keywords":["Endocyte Inc. (NASDAQ:ECYT)","NASDAQ:ECYT"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-fell-the-deepest-in-3-years-after-failed-results-of-ovarian-cancer-drug-trail-21018#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-fell-the-deepest-in-3-years-after-failed-results-of-ovarian-cancer-drug-trail-21018","url":"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-fell-the-deepest-in-3-years-after-failed-results-of-ovarian-cancer-drug-trail-21018","name":"Endocyte, Inc. (NASDAQ:ECYT) Fell The Deepest In 3 Years After Failed Results Of Ovarian Cancer Drug Trail - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-fell-the-deepest-in-3-years-after-failed-results-of-ovarian-cancer-drug-trail-21018#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-fell-the-deepest-in-3-years-after-failed-results-of-ovarian-cancer-drug-trail-21018#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/Endocyte-Inc..gif","datePublished":"2014-05-02T15:47:14+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-fell-the-deepest-in-3-years-after-failed-results-of-ovarian-cancer-drug-trail-21018#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-fell-the-deepest-in-3-years-after-failed-results-of-ovarian-cancer-drug-trail-21018"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-fell-the-deepest-in-3-years-after-failed-results-of-ovarian-cancer-drug-trail-21018#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/Endocyte-Inc..gif","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/05\/Endocyte-Inc..gif","width":1024,"height":512},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/endocyte-inc-nasdaqecyt-fell-the-deepest-in-3-years-after-failed-results-of-ovarian-cancer-drug-trail-21018#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Endocyte, Inc. (NASDAQ:ECYT) Fell The Deepest In 3 Years After Failed Results Of Ovarian Cancer Drug Trail"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e","name":"Greg Folin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","caption":"Greg Folin"},"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/21018","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=21018"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/21018\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/21034"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=21018"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=21018"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=21018"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=21018"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}